HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Denise A. Yardley et al.|Journal of Clinical Oncology|2019Cited by 82